This is from Reddit : Spot on 13D supporters.

New Post Public Reply Private Reply Replies (0) Message Board
onestepahead
929
This is from Reddit : Spot on

13D supporters. (Thoughtful Investing) Send me a link to Incell DX's drug trials. All none of them please. Bruce Patterson's Phase 3 drug trials would be great too. Guessing they have the same link.
Opinion
Here's Cytodyn's. https://clinicaltrials.gov/ct2/results?cond=&...&dist=

22 in total, including a very successful Phase 2 Long Hauler Trial. You realize that there were people in wheel chairs at the beginning of that study, and walked out of it at the end and its not because they were leaning on the arm of Bruce Patterson. You're actually complaining that you can't see a Phase 3 Trial yet when they have 22 different Trials in one stage or another. You proclaim BP as a hero with his none trials and Nader as incompetent with his 22 trials , not to mention some crazy exciting results in Breast Cancer that I won't even get into. You admit the drug works. You admit it should be approved. And yet all your arrows fly around the FDA into Nader, while you lift Bruce Patterson up as the man that would see it done.

Personally, I think Dr. Patterson is a very intelligent and gifted human being. To listen to the man, I find him personally likeable, but he's no replacement for Nader as CEO, and none of you even pretend he is. Whatever he replaces, I have questions. I have concerns about his integrity. That Patent issue and the 13D so called justification is a major problem for me. The lack of transparency is a problem for me. And I really don't like what I've seen out of some of the people that have rallied both to him and Incell DX that used to be very supportive of Leronlimab and Cytodyn and have turned on a dime, much like Thoughtful, and have been so ferocious in their criticisms. The coordination of the message points, and the timing, and the vehement change, it makes me very, very suspicious. Especially when some of these guys are suddenly working with Incell Dx. It's odd.

I imagine Thoughtful will credit his change to the Phase 3 CDO 12 and the missed primary endpoint because the age range wasn't accounted for. Cytodyn's response is they didn't know as much about the disease at the time they created the trial, and they honestly didn't account for it. A definite bummer if so, but that's what they call experience, and that's what these trials are supposed to help acquire.

But I have to point this out. Do you REALLY think Nader designed the study? The 13D's continue to lay that at his feet, like he put it together between meetings and at home while he watched TV. You know as well as I that he hired people to put together and oversee the trial, and the man of honor that he is, he refused to throw anyone under the bus, when there was only personal upside for him do so. All of use would have gone along with it. There were even some that wondered if someone intentionally tanked the study on behalf of Big Pharma. But Nader didn't say anything negative about anyone, to include the FDA for that matter. He actually defended all of them, and I respect that and I give him the benefit of the doubt as a missed opportunity that won't be missed again.

But the 13D solution is to give the company that he single handedly saved, to a group that has NEVER accomplished anything in the range of what we need accomplished. A significant portion of this group by the way has a lot of history with Cytodyn and very little of it is good. Personally, I think it would be a horrible mistake. I find the way this has been presented distasteful. I don't trust the group that has been assembled or the plan that we have yet to see. But it really doesn't matter. Even if I didn't have those issues, I honestly believe there is one man in the world that knows exactly how to run Cytodyn with no loss of momentum, and he's running it. Statistically he's poised. He's got a lot of hooks in the water and I believe in him, and the drug, and the hooks. One is going to hit, and when it does, even if the FDA is as corrupt as so many fear, my prayer is it will be so conclusive that it will overwhelm that as well if it exists.

We are far more poised for success than we were when Thoughtful Investing was telling all of us that $7 a share was a bargain... Nash, Brazil, HIV BLA, Cancer... any one of these hit and Nader will make all of you far more revenue than your loyalty deserves, but that's okay. I'd love to see it happen. But when it does will you put as much energy into apologizing to the man as you've spent vilifying him?

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Off-Broadway Play 'DUST' Raises Autism Support Funds

Updated Category News Views 401

Here's the scoop: an Off-Broadway production just did something many big hitters can't pull off. 'DUST,' a show crafted like a love letter to the American West, managed to rustle up $30,000 for young adults grappled with autism. Partnering with no less than Yale's Cultural Autism Studies and the Ed Asner Family Center, this effort hit the mark in more ways than one. An...

Continue Reading
FuelCell Faces Class Action Crunch as Deadline Looms

Updated Category News Views 239

FuelCell's Legal Storm: What to Know Now You ever get that feeling when your gut knows it all before you even finish reading the headline? Well, buckle up, because FuelCell Energy, Inc. (NASDAQ:FCEL) is staring down a potential class-action train wreck, and they ain't got much track left to skid on before the deadline hits hard on November 10th, 2026. The Crunchy Details...

Continue Reading
Paris Baguette Pioneers Drive-Thru in Oklahoma

Updated Category News Views 659

Tapping The Unseen Potential In Bakery Cafes Every so often a business move comes along that makes you sit up and say, "Why the hell haven't they done this before?" Paris Baguette has finally cracked that code, rolling out its first-ever drive-thru in Moore, Oklahoma. Now, imagine yourself zipping through for a croissant without leaving the comfort of your car seat. Makes...

Continue Reading
MWC26 Doha: Bridging Standards for MENA's Future

Updated Category News Views 157

MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...

Continue Reading
Evaluating GLP-1 Telehealth? Key Questions to Consider

Updated Category News Views 508

Navigating the Landscape of GLP-1 Telehealth Providers In the sprawling jungle of telehealth options for GLP-1 care, it's easy to feel like you're drowning in sameness. Picture this: you land on a sleek page promising the moon and stars, but who knows what's behind the curtain? That's where seasoned advice comes in, like a compass in this murky digital forest. Meant, a...

Continue Reading
ecozy's Brezzano Switch: Brewing Simplicity at Home

Updated Category News Views 499

Breathe the aroma, sip the innovation. ecozy just threw their Brezzano Switch into the arena, and here's the deal: it's a no-nonsense, get-your-caffeine-fix kind of machine aimed at making your mornings simple without compromising on flavor. Unique Features of the Brezzano Switch So, what's cooking? Get this—it's not just any coffee contraption. Built sleek and compact,...

Continue Reading
J&J's New Study: Sjögren’s Solution Insight Sparks Debate

Updated Category News Views 281

Patient-Centric Take on Sjögren's Disease Johnson & Johnson has dropped fresh Phase 2 results on nipocalimab, reminding everyone they're at the helm of reshaping treatments for Sjögren's disease (SjD). A condition leaving about four million folks craving better days, in multiple ways, shines a light on what's gripping patients the hardest. It's hard not to sit up and...

Continue Reading
TCL's Display Future: AI Meets Screens at DTC 2026

Updated Category News Views 440

Exploring New Horizons in Display Technology There's something brewing in Wuhan: a conference that’s shaping up like a tech enthusiast’s dream. This year, it's all about the symbiosis of cutting-edge tech and dazzling visuals as TCL CSOT gears up to unveil advancements at the Global Display Tech-Ecosystem Conference (DTC) 2026. If you're wondering whether this event...

Continue Reading
Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 253

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading
Johnson & Johnson Unveils Promising PsA Treatment Data

Updated Category News Views 282

A Game-Changer in Psoriatic Arthritis Treatment? Johnson & Johnson just tossed a headline-grabbing bone into the world of psoriatic arthritis with their new ICOTYDE results. For anyone tangled in the chronic web of psoriatic arthritis, hearing about a potential new treatment like ICOTYDE comes with cautious hope. Between stiff joints and rashy skin, sufferers are often...

Continue Reading

Top 5 Most Recently Viewed Articles

Cynthia Latham Sells $89K LifeVantage Shares Amid Market Concern

Updated Category News Views 156

Understanding the Recent Insider Sale at Lifevantage Recently, insider trading activity stirred interest as Cynthia Latham, a valued Board Member at Lifevantage (NASDAQ: LFVN), executed a significant sale. This noteworthy transaction occurred on February 13, according to recent filings with the SEC. Details of the Sale The official Form 4 filing disclosed that Latham sold...

Continue Reading
PetScreening, Yardi Partner for Smarter Rental Solutions

Updated Category News Views 25

Rentals Get a Pet-Friendly Upgrade Picture this: you're knee-deep in rental property management, juggling compliance with pet policies and assistance animals. Well, some would say it's about time someone rolled up their sleeves and did something about it. Enter PetScreening and Yardi, who've just announced a partnership aiming to transform the way rental housing handles...

Continue Reading
Celebrating Saudi Net Link's Achievement in Satellite Innovation

Updated Category News Views 313

Saudi Net Link Honored with Excelerator Sustained Excellence Award ST Engineering iDirect has recognized Saudi Net Link (SNL) as the recipient of its prestigious Excelerator Sustained Excellence Award during a recent event. This acknowledgment showcases the importance of enduring partnerships in driving progress within the satellite communications sector. Importance of...

Continue Reading
Investors Urged to Review Legal Options with Cardlytics

Updated Category News Views 113

Understanding Your Rights as a Cardlytics Investor In an ever-evolving market, investors often find themselves navigating challenging waters. If you're an investor in Cardlytics, it’s vital to be aware of your legal options, especially if you've encountered significant financial setbacks. Faruqi & Faruqi, LLP, a well-respected national securities law firm, is currently...

Continue Reading
KuCoin and CryptoStruct Unite for Enhanced Trading Solutions

Updated Category News Views 146

KuCoin and CryptoStruct Unite for Enhanced Trading Solutions KuCoin Institutional, the esteemed division of KuCoin focused on serving professional traders, has recently announced an exciting strategic partnership with CryptoStruct. This collaboration aims to revolutionize the landscape of algorithmic trading by providing institutions with an advanced infrastructure that...

Continue Reading